Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37743427/
Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect
To date, emerging agents effective in cBTKi exposed MCL such as non-covalent BTKi, bispecific T-cell engaging antibodies are yet to be systematically evaluated in CNS MCL.13 We should encourage ongoing early phase studies of novel agents in lymphoma to include cohorts allowing active CNS disease so that patients unfortunate enough to face...
Nine-year Follow-up of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma
Key Points. LR initial therapy for MCL provides durable efficacy with 9-year progression-free survival and overall survival of 51% and 66%, respectivelyChronic
Conclusions/Relevance: LR continues to demonstrate prolonged, durable responses with manageable safety as initial induction therapy.
Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies
AbstractDisclaimer. In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manu
Conclusion: Serious infection and IFI rates are high but similar to those previously described. Risk factors for serious infection included allo-HSCT and corticosteroid use. Targeted antimicrobial prophylaxis should be evaluated in prospective studies in patients on ibrutinib to reduce serious infections and IFI.
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37654003/
Mantle-cell lymphoma (MCL) is a B-cell non-Hodgkin Lymphoma (NHL) with a poor prognosis, at high risk of relapse after conventional treatment. MCL-associated tumour microenvironment (TME) is characterized by M2-like tumour-associated...
Discussion: MCL is an aggressive NHL with a dismal prognosis and high probability of relapse after a conventional immunochemotherapeutic regimen.1 CLL is instead an incurable chronic B-cell malignancy with a higher probability of relapse after several lines of therapies and a non-negligible risk of progression into an aggressive lymphoma. In...
Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37649456/
The incidence and mortality rates of renal cell carcinoma (RCC) have been increasing annually due to obesity and environmental pollution. Although immunotherapy of RCC has been studied for decades, few...
Conclusions/Relevance: By analyzing the results of bibliometrics, national and international researchers can better understand the current research status of RCC immunotherapy and identify new directions for future research. However, the analysis also identified pockets of insularity, highlighting a need for greater collaboration and...